Description: Historically different approaches have been used by actuaries in modeling mortality improvement. The SOA has recently released a framework that practitioners can use to project mortality improvement, providing methodological consistency across a range of applications.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: It has been a little over a year since the release of the Society of Actuaries (SOA) Research Institute's Mortality Improvement Model, MIM-2021. Since then, waves of COVID-19 have continued to occur in the U.S. The uncertainty around the COVID-19 pandemic and the slowing of U.S. general population mortality improvement prior to the pandemic are just a few of the reasons that make developing MI projection scales difficult. Uncoverthe results from intercompany surveys on mortality improvement, including one that addresses COVID-19, discover insights from a mortality expert panel on COVID-19 and future mortality, and discuss enhancements to MIM-2021. By attending the session, you will: - Understand MIM-2021 and 2022 enhancements. - Understand SOA Research Institute activities around COVID-19 and impact on mortality improvement. - Apply research results and insights presented to daily work.

Description: Discuss population mortality improvement trends in the U.S. This will include analysis of cause of death data and trends in mortality pre-pandemic and during the pandemic. We will also discuss ways to think about translating population mortality improvement to an insured population.Learning outcomes includea better understanding of the drivers of recent mortality improvement and insights on how to create a company view on mortality improvement.

Description: Variable annuity (VA) writers are facing many challenges in today's economic environment. Equity market volatility and low interest rates make guaranteed benefits increasingly expensive to hedge. Both GAAP Long Duration Targeted Improvements and the recent VM-21 changes will drive the need to manage the VA business under a new set of lenses. During this session, the presenters will explore the various in-force management tools VA writers have available and comment on their effectiveness.

Description: Under U.S. GAAP long-duration targeted improvements (LDTI), some non-VA annuity products contain features scoped in as 'market risk benefits' (MRBs), which are required to be measured at fair value. For U.S. insurers, the question becomes 'How does the emerging principle-based reserving framework for non-variable annuities compare to the fair value framework for MRBs under LDTI?' See a comparison between these two new measurement models, highlighting some of the key considerations due to the added complexity of these calculations, to help companies strategically plan for their future state.

Description: Join us for discussion about the tax implications for direct writers ceding annuity blocks. The presenters will describe the mechanics and consequences for both onshore and offshore reinsurance arrangements. This will introduce the audience to the tax consequences, with the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are US-based and not US domiciled.

Description: The SOA has conducted a mortality study covering deferred annuities, both fixed and variable. This is a brand new area of analysis for the SOA's Individual Annuity Experience Committee and should be of critical interest to the industry. Previous industry annuitant mortality studies have focused on payout annuities, as well as the specialized structured settlement annuity market. Traditionally, mortality had not been seen as a critical assumption for deferred annuities. As the products have evolved over time, especially with the popularity of enhanced death benefits for variable annuities and guaranteed living benefits for both variable and fixed annuities, mortality has taken on increased importance. The results of this study have recently taken on even greater significance, as regulators are seeking mortality assumptions for the standard projection scenario for VM-22 (fixed annuities), as well as a potential update to those assumptions in VM-21 (variable annuities). By attending the session, you will: - Understand how deferred annuitant mortality compares with established annuitant mortality tables. Note that annuitant mortality tables, including the most recent 2012 tables, were developed based on payout annuitant mortality experience. - Become aware of the differences in mortality experience between fixed and variable annuities. - Gain insights into the effect of various guaranteed benefits on anti-selection and subsequent annuitant mortality, both for death benefits and living benefits. - Understand the durational aspects of emerging mortality experience, particularly for deferred annuities with guaranteed benefits.

Description: The annuity market has been declining while the registered index-linked annuity (RILA) market has been expanding. Find outwhy the market is growing along with key features and considerations for the product from an actuarial perspective. By attending the session, you will: - Explain the increase in consumer demand and product opportunity. - Explain the key features and mechanics of a RILA. - Understand the pricing of RILA product. - Comprehend the key risks and ALM risks associated with RILA. - Explain high-level reserving mechanics of RILA under U.S. GAAP and U.S. statutory frameworks. - Understand the regulatory landscape impacting RILA products.

Description: Discuss a comparison of the U.S. general and insured population mortality experience and how COVID-19 and non-COVID-19 excess deaths impacted the populations differently. Discover the population mortality experience in the UK with a focus on the recent emergence of excess deaths for non-COVID causes. The long-term implications on the insured population will also be explored. Wrap up with a discussion of different conditions of long COVID, including organ impairments.